Qiong Xiao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1380126/publications.pdf

Version: 2024-02-01

18	187	1040056 9	1058476 14
papers	citations	h-index	g-index

18	18	18	239
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Insights into the metabolic characteristics of aminopropanediol analogues of SYLs as S1P1 modulators: from structure to metabolism. European Journal of Pharmaceutical Sciences, 2021, 158, 105608.	4.0	1
2	Formation and Disproportionation of Xanthenols to Xanthenes and Xanthones and Their Use in Synthesis. Journal of Organic Chemistry, 2021, 86, 3334-3343.	3.2	10
3	Synthesis of tetrahydroisoquinolines through TiCl4-mediated cyclization and Et3SiH reduction. Chinese Chemical Letters, 2020, 31, 729-732.	9.0	4
4	A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models. Acta Pharmaceutica Sinica B, 2020, 10, 276-288.	12.0	18
5	Design and synthesis of selective sphingosine-1-phosphate receptor 1 agonists with increased phosphorylation rates. Acta Pharmaceutica Sinica B, 2020, 10, 1134-1142.	12.0	3
6	Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2020, 63, 7986-8002.	6.4	38
7	S1P1-selective agonist prodrug IMMH002 is phosphorylated in rats to form an S-configured enantiomer: Synthesis, verification, and biological activity of the in vivo active metabolite. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127141.	2.2	1
8	Design and synthesis of analogues of the sphingosine-1-phosphate receptor 1 agonist IMMH001 with improved phosphorylation rate in human blood. Bioorganic and Medicinal Chemistry, 2020, 28, 115722.	3.0	0
9	Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis. Frontiers in Pharmacology, 2019, 10, 1085.	3.5	10
10	Asymmetric amination of Î±,Î±-dialkyl substituted aldehydes catalyzed by a simple chiral primary amino acid and its application to the preparation of a S1P₁ agonist. RSC Advances, 2019, 9, 33497-33505.	3.6	3
11	Lig4-4 selectively inhibits TREK-1 and plays potent neuroprotective roles in vitro and in rat MCAO model. Neuroscience Letters, 2018, 671, 93-98.	2.1	16
12	Identification of cytochrome P450 isoforms involved in the metabolism of Syl930, a selective S1PR 1 agonist acting as a potential therapeutic agent for autoimmune encephalitis. Drug Metabolism and Pharmacokinetics, 2017, 32, 53-60.	2.2	2
13	Synthesis, identification, and biological activity of metabolites of two novel selective S1P1 agonists. Bioorganic and Medicinal Chemistry, 2016, 24, 2273-2279.	3.0	6
14	Pharmacokinetics of H002, a novel S1PR1 modulator, and its metabolites in rat blood using liquid chromatographyâ€“tandem mass spectrometry. Acta Pharmaceutica Sinica B, 2016, 6, 576-583.	12.0	5
15	Assembly of substituted phenanthridines via a cascade palladium-catalyzed coupling reaction, deprotection and intramolecular cyclization. RSC Advances, 2016, 6, 19571-19575.	3.6	18
16	Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design. European Journal of Medicinal Chemistry, 2014, 85, 1-15.	5.5	12
17	Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis. Biochemical Pharmacology, 2014, 90, 50-61.	4.4	21
18	Design, synthesis and docking-based 3D-QSAR study of novel 2-substituted 2-aminopropane-1,3-diols as potent and selective agonists of sphingosine-1-phosphate 1 (S1P1) receptor. MedChemComm, 2013, 4, 1267.	3.4	19